4 lines
No EOL
3.2 KiB
Text
4 lines
No EOL
3.2 KiB
Text
"NOFO #","NOFO Title","Research Focus Area","Research Program","Earliest Submission Date","Expiration Date",Summary,"NOFO Posted Date"
|
||
RFA-NS-25-012,"HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)","Preclinical and Translational Research in Pain Management","Development and Optimization of Non-Addictive Therapies to Treat Pain","Sat, 05/18/2024","Sat, 01/16/2027","This notice of funding opportunity (NOFO) aims to encourage research grant applications for initial translational efforts that will enable a drug discovery program for novel, non-opioid, and non-addictive treatments for pain. The program provides funding to develop and validate assays to support a distinct testing funnel and conduct screening efforts to identify and characterize potential therapeutic agents including small molecules, biologics, and natural products. Preliminary in vivo pharmacokinetic, pharmacodynamic, and efficacy studies may also be supported. The goal of this NOFO is to advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program or other later-stage translational programs.","Tue, 03/26/2024 - 12:00pm"
|
||
RFA-NS-25-023,"HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)","Preclinical and Translational Research in Pain Management","Development and Optimization of Non-Addictive Therapies to Treat Pain","Sat, 12/28/2024","Thu, 12/16/2027","This notice of funding opportunity (NOFO) aims to encourage research grant applications for initial translational efforts that will enable a drug discovery program for novel, non-opioid, and non-addictive treatments for pain. The program provides funding to develop and validate assays to support a distinct testing funnel and conduct screening efforts to identify and characterize potential therapeutic agents including small molecules, biologics, and natural products. Preliminary in vivo pharmacokinetic, pharmacodynamic, and efficacy studies may also be supported. The goal of this NOFO is to advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program or other later-stage translational programs.This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the discovery and preclinical development of safe and effective therapeutics to treat pain with little or no addiction liability.","Wed, 09/18/2024 - 12:00pm"
|
||
RFA-NS-24-019,"HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)","Preclinical and Translational Research in Pain Management","Development and Optimization of Non-Addictive Therapies to Treat Pain","Sun, 12/24/2023","Fri, 01/08/2027","The purpose of this notice of funding opportunity (NOFO) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising early therapeutic molecules and to facilitate readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) or other Phase II clinical studies.","Wed, 11/01/2023 - 12:00pm" |